Recent studies uncover various innovations improving cancer therapy and diagnosis. Biokin achieved a Phase 3 success with a bispecific antibody-drug conjugate licensed to Bristol Myers Squibb. New biomarkers and immune checkpoint enhancer agonists reveal potential for personalized oncology treatments. Additionally, advances in spatial proteomics via optoproteomics and AI-powered radiomics models are refining tumor characterization and prognosis. These developments collectively represent strides in precision oncology and immunotherapy modalities.